Search alternatives:
point decrease » point increase (Expand Search)
non decrease » note decreased (Expand Search), fold decrease (Expand Search), mean decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
50 a » 50 μ (Expand Search), 50 _ (Expand Search), 50 c (Expand Search)
point decrease » point increase (Expand Search)
non decrease » note decreased (Expand Search), fold decrease (Expand Search), mean decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
50 a » 50 μ (Expand Search), 50 _ (Expand Search), 50 c (Expand Search)
-
241
-
242
-
243
-
244
-
245
DataSheet5_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx
Published 2021“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”
-
246
-
247
-
248
-
249
Annual number of outpatient visits in all eyes.
Published 2025“…In the recurrence group, BCVA (logMAR) showed no significant improvement over time: 0.37 ± 0.20 preoperatively and 0.35 ± 0.23, 0.35 ± 0.18, 0.31 ± 0.23, 0.34 ± 0.26, 0.28 ± 0.30, and 0.24 ± 0.23 at 1, 3, 6, 12, 24, and 36 months, respectively (Kruskal-Wallis test, p = 0.45). In contrast, the non-recurrence group demonstrated significant and sustained improvement from 0.31 ± 0.25 preoperatively to 0.25 ± 0.25, 0.23 ± 0.26, 0.23 ± 0.28, 0.21 ± 0.27, 0.20 ± 0.30, and 0.16 ± 0.30 at corresponding postoperative time points (Kruskal-Wallis test, p < 0.001; <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0332941#pone.0332941.g005" target="_blank">Fig 5</a>).…”
-
250
-
251
-
252
-
253
-
254
-
255
-
256
-
257
-
258
-
259
Nemp1 supports NE openings in erythroblasts.
Published 2022“…Ery A, B, and C were distinguished based on increasing Ter119 intensity and decreasing nuclear diameter (7.4, 6.4, and 5.4 μm for EryA, B, and C, respectively). …”
-
260